Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 9/2016

06.06.2016 | Original Article

Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV-coinfected patients who achieved sustained virological response

verfasst von: S. Leone, M. Prosperi, S. Costarelli, P. Nasta, F. Maggiolo, S. Di Giambenedetto, A. Saracino, M. Di Pietro, A. Gori

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 9/2016

Einloggen, um Zugang zu erhalten

Abstract

Data on the effects of sustained virologic response (SVR) to hepatitis C virus (HCV) therapy on the outcome of extrahepatic complications are scarce. We conducted this study to assess the impact of SVR on the occurrence of chronic kidney disease (CKD), diabetes mellitus (DM), and cardiovascular disease (CVD) in a cohort of human immunodeficiency virus (HIV)-infected patients. We analyzed coinfected HIV/HCV patients in the Management of Standardized Evaluation of Retroviral HIV Infection (MASTER) cohort. Only event-free patients with a serum HCV-RNA determination at baseline were included. Patients were divided into four groups: INF-exposed with SVR; INF-exposed without SVR; spontaneous HCV clearance; untreated viremic patients. We estimated the incidence of extrahepatic complications and employed Kaplan–Meier curves and Cox regression to assess the association of SVR/INF strata adjusted for a series of confounders. Data from 1676 patients were analyzed (20.29 % started an INF-based regimen). Overall, the incidence of CKD, DM, CVD, and death was 5.32 [95 % confidence interval (CI) 3.99–6.98], 10.13 (95 % CI 8.20–12.37), 6.79 (95 % CI 5.26–8.65), and 13.49 (95 % CI 11.29–16.0) per 1000 person-years of follow-up, respectively. In the Cox model for treated patients, SVR was not associated with a lower risk of CKD, DM, CVD, and death compared to non-SVR. Cirrhosis was significantly associated with a higher risk of CKD [hazard ratio (HR) 2.13; 95 % CI 1.06–4.31], DM (HR 3.48; 95 % CI 2.18–5.57), and death (HR 6.18; 95 % CI 4.1–9.31), but not of CVD (HR 1.14; 95 % CI 0.57–2.3). There are still many unknowns regarding the impact of SVR on the occurrence of extrahepatic complications in coinfected HIV/HCV patients. Further investigations are needed in order to elucidate the role of SVR as an independent prognostic factor for extrahepatic events.
Literatur
1.
2.
Zurück zum Zitat Leone S, Gregis G, Quinzan G, Velenti D, Cologni G, Soavi L, Ravasio V, Ripamonti D, Suter F, Maggiolo F (2011) Causes of death and risk factors among HIV-infected persons in the HAART era: analysis of a large urban cohort. Infection 39:13–20CrossRefPubMed Leone S, Gregis G, Quinzan G, Velenti D, Cologni G, Soavi L, Ravasio V, Ripamonti D, Suter F, Maggiolo F (2011) Causes of death and risk factors among HIV-infected persons in the HAART era: analysis of a large urban cohort. Infection 39:13–20CrossRefPubMed
3.
Zurück zum Zitat Mira JA, Rivero-Juárez A, López-Cortés LF, Girón-González JA, Téllez F, de los Santos-Gil I, Macías J, Merino D, Márquez M, Ríos-Villegas MJ, Gea I, Merchante N, Rivero A, Torres-Cornejo A, Pineda JA; Grupo Andaluz para el Estudio de las Hepatitis Víricas de la Sociedad Andaluza de Enfermedades Infecciosas (2013) Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Clin Infect Dis 56:1646–1653CrossRefPubMed Mira JA, Rivero-Juárez A, López-Cortés LF, Girón-González JA, Téllez F, de los Santos-Gil I, Macías J, Merino D, Márquez M, Ríos-Villegas MJ, Gea I, Merchante N, Rivero A, Torres-Cornejo A, Pineda JA; Grupo Andaluz para el Estudio de las Hepatitis Víricas de la Sociedad Andaluza de Enfermedades Infecciosas (2013) Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Clin Infect Dis 56:1646–1653CrossRefPubMed
4.
Zurück zum Zitat Berenguer J, Alvarez-Pellicer J, Martín PM, López-Aldeguer J, Von-Wichmann MA, Quereda C, Mallolas J, Sanz J, Tural C, Bellón JM, González-García J; GESIDA3603/5607 Study Group (2009) Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 50:407–413CrossRefPubMed Berenguer J, Alvarez-Pellicer J, Martín PM, López-Aldeguer J, Von-Wichmann MA, Quereda C, Mallolas J, Sanz J, Tural C, Bellón JM, González-García J; GESIDA3603/5607 Study Group (2009) Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 50:407–413CrossRefPubMed
5.
Zurück zum Zitat Berenguer J, Rodríguez E, Miralles P, Von Wichmann MA, López-Aldeguer J, Mallolas J, Galindo MJ, Van Den Eynde E, Téllez MJ, Quereda C, Jou A, Sanz J, Barros C, Santos I, Pulido F, Guardiola JM, Ortega E, Rubio R, Jusdado JJ, Montes ML, Gaspar G, Esteban H, Bellón JM, González-García J; GESIDA HIV/HCV Cohort Study Group (2012) Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus. Clin Infect Dis 55:728–736CrossRefPubMed Berenguer J, Rodríguez E, Miralles P, Von Wichmann MA, López-Aldeguer J, Mallolas J, Galindo MJ, Van Den Eynde E, Téllez MJ, Quereda C, Jou A, Sanz J, Barros C, Santos I, Pulido F, Guardiola JM, Ortega E, Rubio R, Jusdado JJ, Montes ML, Gaspar G, Esteban H, Bellón JM, González-García J; GESIDA HIV/HCV Cohort Study Group (2012) Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus. Clin Infect Dis 55:728–736CrossRefPubMed
6.
Zurück zum Zitat Aleman S, Rahbin N, Weiland O, Davidsdottir L, Hedenstierna M, Rose N, Verbaan H, Stål P, Carlsson T, Norrgren H, Ekbom A, Granath F, Hultcrantz R (2013) A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis 57:230–236CrossRefPubMed Aleman S, Rahbin N, Weiland O, Davidsdottir L, Hedenstierna M, Rose N, Verbaan H, Stål P, Carlsson T, Norrgren H, Ekbom A, Granath F, Hultcrantz R (2013) A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis 57:230–236CrossRefPubMed
7.
Zurück zum Zitat Bedimo R, Westfall AO, Mugavero M, Drechsler H, Khanna N, Saag M (2010) Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV Med 11:462–468PubMed Bedimo R, Westfall AO, Mugavero M, Drechsler H, Khanna N, Saag M (2010) Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV Med 11:462–468PubMed
8.
Zurück zum Zitat Butt AA, McGinnis K, Rodriguez-Barradas MC, Crystal S, Simberkoff M, Goetz MB, Leaf D, Justice AC; Veterans Aging Cohort Study (2009) HIV infection and the risk of diabetes mellitus. AIDS 23:1227–1234CrossRefPubMedPubMedCentral Butt AA, McGinnis K, Rodriguez-Barradas MC, Crystal S, Simberkoff M, Goetz MB, Leaf D, Justice AC; Veterans Aging Cohort Study (2009) HIV infection and the risk of diabetes mellitus. AIDS 23:1227–1234CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Peters L, Grint D, Lundgren JD, Rockstroh JK, Soriano V, Reiss P, Grzeszczuk A, Sambatakou H, Mocroft A, Kirk O; EuroSIDA in EuroCoord (2012) Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. AIDS 26:1917–1926CrossRefPubMed Peters L, Grint D, Lundgren JD, Rockstroh JK, Soriano V, Reiss P, Grzeszczuk A, Sambatakou H, Mocroft A, Kirk O; EuroSIDA in EuroCoord (2012) Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. AIDS 26:1917–1926CrossRefPubMed
10.
Zurück zum Zitat Torti C, Raffetti E, Donato F, Castelli F, Maggiolo F, Angarano G, Mazzotta F, Gori A, Sighinolfi L, Pan A, Cauda R, Scalzini A, Quiros-Roldan E, Nasta P, Gregis G, Benatti S, Digiambenedetto S, Ladisa N, Giralda M, Saracino A, Castelnuovo F, Di Pietro M, Lo Caputo S, Lapadula G, Costarelli S, Lorenzotti S, Mazzini N, Paraninfo G, Casari S, Focà E, Pezzoli C, Fabbiani M, Monno L, Pierotti P, Ble C, Leone S, Postorino MC, Fornabaio C, Zacchi F, Zoncada A, Carosi G (2015) Cohort profile: standardized management of antiretroviral therapy cohort (MASTER Cohort). Int J Epidemiol. 2015 Oct 7. pii: dyv192 Torti C, Raffetti E, Donato F, Castelli F, Maggiolo F, Angarano G, Mazzotta F, Gori A, Sighinolfi L, Pan A, Cauda R, Scalzini A, Quiros-Roldan E, Nasta P, Gregis G, Benatti S, Digiambenedetto S, Ladisa N, Giralda M, Saracino A, Castelnuovo F, Di Pietro M, Lo Caputo S, Lapadula G, Costarelli S, Lorenzotti S, Mazzini N, Paraninfo G, Casari S, Focà E, Pezzoli C, Fabbiani M, Monno L, Pierotti P, Ble C, Leone S, Postorino MC, Fornabaio C, Zacchi F, Zoncada A, Carosi G (2015) Cohort profile: standardized management of antiretroviral therapy cohort (MASTER Cohort). Int J Epidemiol. 2015 Oct 7. pii: dyv192
11.
Zurück zum Zitat Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, Sulkowski SM, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M; APRICOT Clinical Investigators (2006) Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43:1317–1325CrossRefPubMed Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, Sulkowski SM, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M; APRICOT Clinical Investigators (2006) Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43:1317–1325CrossRefPubMed
12.
Zurück zum Zitat Centers for Disease Control and Prevention (CDC) (1992) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 41:1–19 Centers for Disease Control and Prevention (CDC) (1992) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 41:1–19
13.
Zurück zum Zitat Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, Albrecht J (2000) Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 32:1131–1137CrossRefPubMed Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, Albrecht J (2000) Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 32:1131–1137CrossRefPubMed
14.
Zurück zum Zitat Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kuroki T, Nishiguchi S, Sata M, Yamada G, Fujiyama S, Yoshida H, Omata M (2000) Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 132:517–524CrossRefPubMed Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kuroki T, Nishiguchi S, Sata M, Yamada G, Fujiyama S, Yoshida H, Omata M (2000) Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 132:517–524CrossRefPubMed
15.
Zurück zum Zitat Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, Albrecht J (2002) Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122:1303–1313CrossRefPubMed Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, Albrecht J (2002) Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122:1303–1313CrossRefPubMed
16.
Zurück zum Zitat Labarga P, Fernandez-Montero JV, Barreiro P, Pinilla J, Vispo E, de Mendoza C, Plaza Z, Soriano V (2014) Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy. J Viral Hepat 21:475–479CrossRefPubMed Labarga P, Fernandez-Montero JV, Barreiro P, Pinilla J, Vispo E, de Mendoza C, Plaza Z, Soriano V (2014) Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy. J Viral Hepat 21:475–479CrossRefPubMed
17.
18.
Zurück zum Zitat Ahmadieh H, Azar ST (2014) Liver disease and diabetes: association, pathophysiology, and management. Diabetes Res Clin Pract 104:53–62CrossRefPubMed Ahmadieh H, Azar ST (2014) Liver disease and diabetes: association, pathophysiology, and management. Diabetes Res Clin Pract 104:53–62CrossRefPubMed
19.
Zurück zum Zitat Bruno R, Sacchi P, Puoti M, Maiocchi L, Patruno S, Carosi G, Filice G (2007) Natural history of compensated viral cirrhosis in a cohort of patients with HIV infection. J Acquir Immune Defic Syndr 46:297–303CrossRefPubMed Bruno R, Sacchi P, Puoti M, Maiocchi L, Patruno S, Carosi G, Filice G (2007) Natural history of compensated viral cirrhosis in a cohort of patients with HIV infection. J Acquir Immune Defic Syndr 46:297–303CrossRefPubMed
20.
Zurück zum Zitat Grint D, Peters L, Rockstroh JK, Rakmanova A, Trofimova T, Lacombe K, Karpov I, Galli M, Domingo P, Kirk O, Lundgren JD, Mocroft A; EuroSIDA in EuroCoord (2015) Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals. AIDS 29:1205–1215CrossRefPubMed Grint D, Peters L, Rockstroh JK, Rakmanova A, Trofimova T, Lacombe K, Karpov I, Galli M, Domingo P, Kirk O, Lundgren JD, Mocroft A; EuroSIDA in EuroCoord (2015) Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals. AIDS 29:1205–1215CrossRefPubMed
21.
Zurück zum Zitat Mocroft A, Ryom L, Begovac J, Monforte AD, Vassilenko A, Gatell J, Florence E, Ormaasen V, Kirk O, Lundgren JD; EuroSIDA in EuroCOORD (2014) Deteriorating renal function and clinical outcomes in HIV-positive persons. AIDS 28:727–737CrossRefPubMed Mocroft A, Ryom L, Begovac J, Monforte AD, Vassilenko A, Gatell J, Florence E, Ormaasen V, Kirk O, Lundgren JD; EuroSIDA in EuroCOORD (2014) Deteriorating renal function and clinical outcomes in HIV-positive persons. AIDS 28:727–737CrossRefPubMed
22.
Zurück zum Zitat Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding PA, Shlipak MG (2010) Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation 121:651–658CrossRefPubMedPubMedCentral Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding PA, Shlipak MG (2010) Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation 121:651–658CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Bandera A, Gori A, Sabbatini F, Madeddu G, Bonora S, Libertone R, Mastroianni C, Bonfanti P, d’Arminio Monforte A, Cozzi-Lepri A; Icona Foundation Study Group (2015) Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy. PLoS One 10:e0124252CrossRefPubMedPubMedCentral Bandera A, Gori A, Sabbatini F, Madeddu G, Bonora S, Libertone R, Mastroianni C, Bonfanti P, d’Arminio Monforte A, Cozzi-Lepri A; Icona Foundation Study Group (2015) Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy. PLoS One 10:e0124252CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL (2000) Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 133:592–599CrossRefPubMed Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL (2000) Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 133:592–599CrossRefPubMed
25.
Zurück zum Zitat Mehta SH, Brancati FL, Strathdee SA, Pankow JS, Netski D, Coresh J, Szklo M, Thomas DL (2003) Hepatitis C virus infection and incident type 2 diabetes. Hepatology 38:50–56CrossRefPubMed Mehta SH, Brancati FL, Strathdee SA, Pankow JS, Netski D, Coresh J, Szklo M, Thomas DL (2003) Hepatitis C virus infection and incident type 2 diabetes. Hepatology 38:50–56CrossRefPubMed
26.
Zurück zum Zitat Butt AA, Fultz SL, Kwoh CK, Kelley D, Skanderson M, Justice AC (2004) Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection. Hepatology 40:115–119CrossRefPubMed Butt AA, Fultz SL, Kwoh CK, Kelley D, Skanderson M, Justice AC (2004) Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection. Hepatology 40:115–119CrossRefPubMed
27.
Zurück zum Zitat Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group, Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, Law M, Monforte Ad, Kirk O, Friis-Moller N, Phillips A, Reiss P, El Sadr W, Pradier C, Worm SW (2010) Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 24:1537–1548 Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group, Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, Law M, Monforte Ad, Kirk O, Friis-Moller N, Phillips A, Reiss P, El Sadr W, Pradier C, Worm SW (2010) Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 24:1537–1548
28.
Zurück zum Zitat Elkrief L, Chouinard P, Bendersky N, Hajage D, Larroque B, Babany G, Kutala B, Francoz C, Boyer N, Moreau R, Durand F, Marcellin P, Rautou PE, Valla D (2014) Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. Hepatology 60:823–831CrossRefPubMed Elkrief L, Chouinard P, Bendersky N, Hajage D, Larroque B, Babany G, Kutala B, Francoz C, Boyer N, Moreau R, Durand F, Marcellin P, Rautou PE, Valla D (2014) Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. Hepatology 60:823–831CrossRefPubMed
29.
Zurück zum Zitat Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska JD, de Wit S, Law M, el Sadr W, Kirk O, Friis-Moller N, Monforte Ad, Phillips AN, Sabin CA, Lundgren JD; D:A:D Study Group (2014) Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet 384:241–248CrossRefPubMed Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska JD, de Wit S, Law M, el Sadr W, Kirk O, Friis-Moller N, Monforte Ad, Phillips AN, Sabin CA, Lundgren JD; D:A:D Study Group (2014) Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet 384:241–248CrossRefPubMed
30.
Zurück zum Zitat Petta S, Macaluso FS, Craxì A (2014) Cardiovascular diseases and HCV infection: a simple association or more? Gut 63:369–375CrossRefPubMed Petta S, Macaluso FS, Craxì A (2014) Cardiovascular diseases and HCV infection: a simple association or more? Gut 63:369–375CrossRefPubMed
31.
Zurück zum Zitat Chew KW, Hua L, Bhattacharya D, Butt AA, Bornfleth L, Chung RT, Andersen JW, Currier JS (2014) The effect of hepatitis C virologic clearance on cardiovascular disease biomarkers in human immunodeficiency virus/hepatitis C virus coinfection. Open Forum Infect Dis 1:ofu104CrossRefPubMedPubMedCentral Chew KW, Hua L, Bhattacharya D, Butt AA, Bornfleth L, Chung RT, Andersen JW, Currier JS (2014) The effect of hepatitis C virologic clearance on cardiovascular disease biomarkers in human immunodeficiency virus/hepatitis C virus coinfection. Open Forum Infect Dis 1:ofu104CrossRefPubMedPubMedCentral
Metadaten
Titel
Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV-coinfected patients who achieved sustained virological response
verfasst von
S. Leone
M. Prosperi
S. Costarelli
P. Nasta
F. Maggiolo
S. Di Giambenedetto
A. Saracino
M. Di Pietro
A. Gori
Publikationsdatum
06.06.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 9/2016
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-016-2692-y

Weitere Artikel der Ausgabe 9/2016

European Journal of Clinical Microbiology & Infectious Diseases 9/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.